Disability and health-related quality of life at baseline and 12 months
| Adalimumab group | Placebo-group | p Value between groups | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 12 months | 0–12 months | Baseline | 12 months | 0–12 months | 12 months | 0–12 months | |
| HAQ (0–3) | 1.13 (0.17–2.58) | 0.25 (0–1.44) | −0.88 (−2.46–0.13) | 1.00 (0.25–2.31) | 0.13 (0–1.5) | −0.63 (−1.82–0.38) | 0.14 | 0.012 |
| SF-12 PCS (0–100) | 30.9 (13.1–50.6) | 49.2 (29.9–56.6) | 13.2 (−2.3–33.0) | 31.7 (19.3–44.5) | 43.3 (26.1–55.8) | 10.6 (−11.2–22.7) | 0.016 | 0.015 |
| SF-12 MCS (0–100) | 47.0 (28.6–60.6) | 55.7 (35.8–62.6) | 5.5 (−8.5–20.1) | 46.7 (25.7–60.1) | 54.8 (40.4–63.7) | 4.3 (−9.3–27.4) | 0.68 | 0.83 |
| EQ-5D (0–1) | 0.61 (0.17–0.80) | 0.82 (0.38–1.00) | 0.22 (−0.05–0.67) | 0.64 (0.22–0.80) | 0.78 (0.49–1.00) | 0.20 (−0.06–0.56) | 0.04 | 0.095 |
Values presented as medians (5th/95th percentile ranges) or % of patients. p Values for differences between two treatment groups by Mann–Whitney U test or Fisher's exact test. Baseline values did not differ statistically significant between groups.
DMARD, disease modifying antirheumatic drug; EQ-5D, European quality of life-5 dimensions; HAQ, Health Assessment Questionnaire; SF12 MCS, Short Form 12-item Survey V.2 Health Survey Mental Component Score; SF12 PCS, Short Form 12-item Survey V.2 Health Survey Physical Component Score.